ABSI AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ABSI Current Performance
2.28%
Absci corp
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ABSI
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
TWST | Twist bioscience corp | 3 | 5 | 4 | 3 | 1 | |
RXRX | Recursion pharmaceuticals inc | 2 | 2 | 4 | 3 | 1 | |
MURA | Mural oncology plc | - | 3 | 2 | - | 1 | |
GLUE | Monte rosa therapeutics inc | 1 | 3 | 2 | 1 | 1 | |
PACB | Pacific biosciences of california inc | 2 | 3 | 2 | 2 | 1 |
- TWST Twist bioscience corpValue 3Trend 5Swing Trading 4Whale Interest 3Dividend 1See more
ABSI Profile
Absci Corporation is a generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. It has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The Company uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The Company supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. It reconstructs prevalent immune-response molecules, such as antibodies from disease tissue and identify their corresponding antigens, offering new therapeutic targets.